PTX3, Human, mAb MNB1, immuno assay antibody

Catalog #: HM2241-IA
Quantity: 0.5 mg

Original supplier of innate immunity products since 1994.

Our commitment to quality: Read more!

Contact our support team for more product information.

Can't find your application for a product? Request a sample!

The monoclonal antibody MNB1 (previously known as clone 16B5) recognizes human pentraxin 3 (PTX3), belonging to the long pentraxin family. PTX3 is an acute-phase glycoprotein of ~45 kDa with glycosylation accounting for about 10% of its molecular weight. PTX3 has a complex oligomeric structure with protomers linked to each other by disulfide bonds. PTX3 expression is triggered by inflammatory cytokines, resulting in higher levels of circulating PTX3. Several cell types have been reported to produce PTX3, namely macrophages, endothelial cells, neutrophils and synoviocytes. PTX3 is involved in host defense against pathogen infection, in the regulation of the scavenger activity of macrophages and dendritic cells, and in modulation of complement activity by binding to C1q. Furthermore, PTX3 has been implicated in matrix deposition of cumulus cells. Moreover, PTX3 interacts with other biologically active molecules, causing their functional blockade. This has been demonstrated for fibroblast growth factor-2 (FGF-2), for which PTX3 acts as an inhibitor, leading to inhibition of angiogenesis. PTX3, like other pentraxins C-reactive protein (CRP) and serum amyloid P component (SAP), binds apoptotic cells and debris. PTX3 is useful as an early indicator of myocyte irreversible injury in ischemic cardiomyopathy. PTX3 is not only involved in inflammatory vessel diseases related to atherosclerosis, but also in pre-eclampsia and systemic small vessel ANCA-associated vasulitis, in which neutrophils are key players. The relationship between tissue damage and pentraxin generation is stringent in acute injuries. PTX3 tunes self-non-self discrimination and tissue repair due to the recognition of diverse ligands by PTX3 and through regulation of effector pathways.


Catalog number HM2241-IA
Product type Monoclonal antibodies
Quantity 0.5 mg
Formulation 0.5 mg of 0.2 μm filtered protein G purified antibody solution in PBS (exact concentration is indicated on the label).
Application FC, FS, IA, W
Application Notes IA: the antibody can be used as detection antibody.
W: Reduced sample treatment. The expected band sizes are approximately 42 and 90 kDa.
Immunogen Human recombinant PTX3
Isotype Mouse IgG2b
Species Human
Alias PTX3, Pentraxin-related protein PTX3, Tumor necrosis factor-inducible gene 14 protein, TSG-14
Gene name: PTX3, TNFAIP5, TSG14
Storage and stability Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.
Precautions For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use or derivation of this product.
Disease Cardiology and metabolism, Infectious diseases
  • Use:
    Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
1. Bottazzi, B et al; Multimer Formation and Ligand Recognition by the Long Pentraxin PTX3. JBC 1997, 272: 32817
2. Camozzi, M et al; Identification of an Antiangiogenic FGF2-binding Site in the N Terminus of the Soluble Pattern Recognition Receptor PTX3*. JBC 2006, 281:22605
3. Jaillon, S et al; The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007, 204: 793
4. Jaillon, S et al. Endogenous PTX3 translocates at the membrane of late apoptotic human neutrophils and is involved in their engulfment by macrophages. Cell Death Diff 2009, 16: 465-474
5. Hamon, Y et al, Proteolytic cleavage of the long pentraxin PTX3 in the airways of cystic fibrosis patients. Inn Imm 2013, 19:611